Indoor Air Filtration and Young Adults Health Study
NCT05172388, Not applicable, Completed, Peking University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Indoor Air Filtration and Young Adults Health Study | ClinicalTrials.gov |
| NCT number | NCT05172388 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 81 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Peking University | ClinicalTrials.gov |
| Conditions | Cardiopulmonary Diseases | ClinicalTrials.gov |
| Interventions | Air purifier | ClinicalTrials.gov |
| First posted | 2021-12-29 | ClinicalTrials.gov |
| Last updated | 2022-10-13 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes in heart rate variability | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Including the standard deviation of all normal-to-normal R-R intervals (SDNN) in millisecond, standard deviation of sequential five-minute R-R interval means (SDANN) in millisecond, root-mean-square difference of successive normal R-R intervals (rMSSD) in millisecond, low frequency (LF) in squared millisecond, and high frequency (HF) in squared millisecond. | ClinicalTrials.gov |
| Primary | Changes in blood pressure | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Including the systolic blood pressure (SBP) in mmHg, diastolic blood pressure (DBP) in mmHg, and pulse pressure (PP) in mmHg. | ClinicalTrials.gov |
| Primary | Changes in pulmonary function | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Including forced expiratory volume in 1 s (FEV1) in liter, forced vital capacity (FVC) in liter, forced expiratory volume in 1 s (FEV1) / forced vital capacity (FVC) ratio, and peak expiratory flow (PEF) in liter per second. | ClinicalTrials.gov |
| Secondary | Changes in levels of airway inflammation | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Respiratory inflammation Fractional exhaled nitric oxide (FeNO) test would be conducted. | ClinicalTrials.gov |
| Secondary | Changes in levels of C-reactive protein (CRP) | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Examining the C-reactive protein (CRP) in blood sample to characterize the levels of inflammation. | ClinicalTrials.gov |
| Secondary | Changes in levels of 8-hydroxydeoxyguanosine (8-OHdG) | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Examining the 8-hydroxydeoxyguanosine (8-OHdG) in urine sample to characterize the levels of oxidative stress. | ClinicalTrials.gov |
| Secondary | Changes in levels of sleep-related parameters | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Including time in bed in minute, total sleep time and sleep stage time in minute. The time in bed and total sleep time would be calculated to sleep efficiency in percentage. | ClinicalTrials.gov |
| Secondary | Changes in levels of sleep-breathing parameters | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Including blood oxygen saturation in percentage and heart rate in bpm. | ClinicalTrials.gov |
| Secondary | Changes in levels of cognitive function | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Including short-term memory and delayed memory in unit measured by the standard Stroop Test, as well as executive function in unit measured by the Harmonized Cognitive Assessment Protocol. | ClinicalTrials.gov |
| Secondary | Changes in levels of cognitive function-related biomarkers | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Including serum brain derived nerve factor (BDNF) in ng/mL, S100B protein in ng/mL, and neuron-specific-enolase (NSE) in ng/mL. | ClinicalTrials.gov |
| Secondary | Changes in levels of blood cell parameters | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Including white blood cells in unit, red blood cells in unit, and platelets in unit measured by blood routine examination. | ClinicalTrials.gov |
| Secondary | Changes in levels of systematic inflammation and oxidative stress indicators | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Including interleukin-6 (IL-6) in unit, IL-8 in unit, IL-10 in unit, IL-13 in unit, IL-5 in unit, IL-1β in unit, IL-17A in unit, IL-12p70 in unit, tumor necrosis factor-α (TNF-α) in unit, interferon-γ (IFN-γ) in unit, monocyte chemoattratctant protein-1 (MCP-1) in unit, angiotensin II (Ang-II) in unit, superoxide dismutase (SOD) in unit, glutathione (GSH) in unit, nitric oxide levels (NOX) in unit. | ClinicalTrials.gov |
| Secondary | Changes in levels of glucose metabolites in serum | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Serum samples were collected for targetted glucose metabolomics analysis using the gas chromatography and mass spectrometry (GC-MS). | ClinicalTrials.gov |
| Secondary | Changes in levels of neurotransmitter metabolites in serum | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Serum samples were collected for targetted neurotransmitter metabolomics analysis using the gas chromatography and mass spectrometry (GC-MS). | ClinicalTrials.gov |
| Secondary | Changes in levels of microbiomics in nasal mucus | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Nasal mucus samples were collected for microbiomics analysis to examine the microbial community abundance (α-diversity). | ClinicalTrials.gov |
| Secondary | Changes in levels of microbiomics in EBC | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | EBC samples were collected for microbiomics analysis to examine the microbial community abundance (α-diversity). | ClinicalTrials.gov |
| Secondary | Changes in levels of pituitary-related hormones | Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention) | Including serum levels of cortisol, adreno-cortico-tropic-hormone (ACTH), and thyroid stimulating hormone (TSH). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)